Leading Australian cancer researcher Professor Wayne Tilley has today been presented with a $2.5 million Breast & Prostate Cancer Linkage Grant, thanks to a groundbreaking collaboration between the National Breast Cancer Foundation (NBCF) and the Movember Foundation in Australia.
(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.
(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.
(Reuters) - Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.
(Norwegian University of Science and Technology) Many patients are treated for prostate cancer unnecessarily. Norwegian researchers are working to reduce overtreatment of prostate cancer while at the same time trying to detect the most high-risk patients. They've just been awarded EUR 1.5 million in EU support.
There is a new technology available that can help with both predicting prostate cancer aggressiveness and detecting prostate cancer. It's called fusion guided biopsy and it greatly improves on the standard biopsy technique.
A man in Australia gave himself cyanide poisoning while consuming apricot kernels meant to prevent his prostate cancer from returning.
The major health news story last week was on a re-assessment of prostate cancer screening published in the Annals of Internal Medicine. The study’s release generated stories in the New York Times, TIME, Consumer Reports, STAT, ABS-CBN News (Philippines) and the LA Times, among others. The reporting confirms what we already know about the PSA test […]
Groundbreaking research could reduce the recurrence of prostate cancer in males, a new study reports.
September is prostate cancer awareness month and helps shed information on the most common cancer affecting men. About 1 in 7 men have a prostate cancer risk with them developing the condition at some point in their lifetime. We at … The...Show More Summary
(European Society for Medical Oncology) Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.
(Society of Nuclear Medicine) Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The study is presented in the featured basic article of the September issue of the Journal of Nuclear Medicine.
PRESS RELEASE: Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy (RT), announced that the International Journal...
A diagnosis of prostate cancer can feel overwhelming for a man. Foremost on their mind is usually what’s the best way to
When it comes to screening for prostate cancer, there’s been a dizzying back and forth over how effective the inexpensive blood test actually is. Here’s what the latest data shows
Researchers have found that PARP inhibitors - a class of drugs used to treat breast cancer - may also benefit men with prostate cancer.
(University of Surrey) Groundbreaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports.
A new review suggests that - contrary to current USPSTF guidelines - PSA screening significantly reduces the risk of death to prostate cancer.
After years of growing doubt about the value of screening men for prostate cancer, a new analysis of existing clinical trial evidence has found that when men between 55 and 70 get the prostate-specific antigen (PSA) test, the result is lives saved. In 2009, a New England Journal of Medicine editorialist...
HMM: Hormone Treatment for Prostate Cancer Tied to Heart Risks. Testosterone-blocking can produce a rather large increase in risk of heart failure and arrhythmia, and also a substantial increase in dementia risk.